已收盤 05-08 16:00:00 美东时间
+0.050
+1.43%
今日重点评级关注:Piper Sandler:维持Aclaris Therapeutics"超配"评级,目标价从7美元升至11美元;Evercore ISI集团:维持BioMarin Pharmaceutical"跑赢大市"评级,目标价从110美元升至120美元
05-06 11:29
Stephens & Co. analyst Charles Nabhan downgrades Repay Holdings (NASDAQ:RPAY) from Overweight to Equal-Weight and lowers the price target from $7 to $3.75.
05-05 22:06
U.S. RESEARCH ROUNDUP-Applied Materials, Axsome Therapeutics, Onsemi May 5 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Applied Materials, Axsome Therapeutics and Onsemi on Tuesday. HIGHLIGHTS * Applied Materials AMAT
05-05 15:07
<span style="color:#999999;">编者按:聚焦公司高管观点与展望,深挖业绩背后的信息,助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 根据Repay业绩会实录,以下是2026年第一季度财务业绩回顾摘要: ## 1. 财务业绩 **营收表现:** 第一季度总营收8,080万美元,同比增长4%。其中消费者支付业务营收同比增长4%,主要受益于新企业客户实施和支付渠道扩展;商业支付业务营收同比增长18%,剔除政治媒体贡献后标准化增长约16%。 **盈利能力:** 调整后EBITDA为3,440万美元,EBITDA利润率约43%。调整后净利润1,940万美元,每股收益0.22美元。 **现金流状况:** 自由现金流540万美元,自由现金流转换率16%。期间支付约1,500万美元税收应收协议款
05-05 12:20
Repay Holdings ( ($RPAY) ) has issued an announcement. Repay Holdings reported ...
05-05 04:35
Repay Holdings Corporation (NASDAQ:RPAY) ("REPAY" or the "Company"), a leading provider of integrated payment processing solutions, today announced that its Board of Directors (the "Board") unanimously rejected the
05-05 04:33
Repay Holdings (NASDAQ:RPAY) affirms FY2026 sales outlook from $340.000 million-$346.000 million to $340.000 million-$346.000 million vs $341.245 million estimate.
05-05 04:21
Repay Hldgs (NASDAQ:RPAY) reported quarterly earnings of $0.22 per share which beat the analyst consensus estimate of $0.21 by 4.76 percent. This is unchanged from the same period last year. The company reported
05-05 04:20
持有Repay Holdings约13%股份的大股东Forager Capital Management周一发表声明,指责该公司董事会自其提出收购提议以来已过去...
05-05 03:54
Companies Reporting Before The Bell • Pulse Biosciences (NASDAQ:PLSE) is likely...
05-04 19:11